Skip to main content
. Author manuscript; available in PMC: 2019 Aug 9.
Published in final edited form as: Cancer Immunol Res. 2018 Mar 27;6(5):605–616. doi: 10.1158/2326-6066.CIR-17-0314

Figure 2.

Figure 2.

A BiTE-armed oncolytic adenovirus improves tumor killing of CART cells without compromising their safety profile. A, Schematic representation of the oncolytic viruses (OAd and OAd-BiTE). B-D, A cytotoxicity assay was used to evaluate the lysis of target cells over a 140-hour period. The mean ± SD of duplicates is shown. Representative of two to four independent experiments. E, Target cells were infected with virus and 24 hours later T cells were added at the indicated E:T ratios. Specific cytolysis was determined by flow cytometry 48 hours after T-cell addition to the cultures. F, Intracellular cytokine staining for TNFα and IFNγ in T cells after coculture with human primary or tumor cells for 20 hours.